10 Pfizer business development leaders
Oncology deals are the thread for three of these Pfizer business development leaders, including the Oncology Search & Evaluation Lead, while the rest cover outlicensing, deal integration, licensing, corporate development for vaccines and internal medicine, and worldwide business development. All ten are in current Pfizer roles and six hold senior director titles, a fit for a biotech pitching an asset, an outlicensing negotiation or post-acquisition planning.
Professionals to explore
Anne-Marie Mueller
LinkedInExperience: Senior Director, R&D Business Development, Oncology and Diagnostics · Pfizer
$943 per 30-minute call
Licensing from both the academic and the Pfizer side is the angle for Anne-Marie Mueller, Senior Director, R&D Business Development, Oncology and Diagnostics at Pfizer since 2023, right after Director, Worldwide R&D Business Development (2010-2023), a role spent leading, negotiating, executing and managing all types of technology licensing. Anne-Marie was Senior Director, Office of Technology Management at the Salk Institute for Biological Studies (1992-2008).
Is this you? Claim your profile and get paid for calls.
Hilde Stubdal
LinkedInExperience: Executive Director, Worldwide Business Development, Oncology Search & Evaluation Lead · Pfizer
$1,211 per 30-minute call
How oncology assets are screened is the question for Hilde Stubdal, Executive Director, Worldwide Business Development, Oncology Search & Evaluation Lead at Pfizer since 2019, right after Executive Director, External Science, Immuno-oncology Lead (2018-2019). Hilde was Principal at BioAssess LLC - Business Development Consulting (2013-2018) and held Corporate Development, Licensing and M&A at Onyx Pharmaceuticals, Inc., an Amgen subsidiary (2008-2013).
Is this you? Claim your profile and get paid for calls.
Jackeline Ferrigno
LinkedInExperience: Director Of Business Development & Licensing · Pfizer
$606 per 30-minute call
Director Of Business Development & Licensing at Pfizer since 2014, Jackeline Ferrigno was Global Director, Marketing Research at Pfizer (2011-2014) right before. Jackeline's experience spans business development, M&A, strategic planning, finance and marketing, including licensing, acquisitions, divestitures, due diligence and negotiations, which fits questions on the commercial case behind a licensing deal.
Is this you? Claim your profile and get paid for calls.
Kelly Callahan
LinkedInExperience: Director, R&D Business Development (Oncology) · Pfizer
$606 per 30-minute call
Kelly Callahan has been Director, R&D Business Development (Oncology) at Pfizer since 2024, a director-level role in the Research department, after Associate Director in the same group earlier that year. At Seagen, Kelly was Associate Director, Corporate Development (2022-2023), Senior Manager Corporate Development (2020-2022) and Manager Corporate Development (2018-2020), so Kelly can compare oncology deal work at a biotech and at Pfizer.
Is this you? Claim your profile and get paid for calls.
Leslie Coney
LinkedInExperience: Senior Director Business Development · Pfizer
$875 per 30-minute call
Leslie Coney has been Senior Director Business Development at Pfizer since 2017 and Director, Worldwide Business Development there since 2011, identifying and closing transactions including research collaborations, in-licensing, out-licensing, co-development and co-commercialization agreements. Leslie was also Director, Business Development at Biogen (from 2007), and Associate Director, Corporate Development (2002-2007) and Associate Director Technology Transfer (1998-2002) at Biogen Idec.
Is this you? Claim your profile and get paid for calls.
Marion Fitzpatrick
LinkedInExperience: Senior Director, Portfolio Leader Outlicensing, Business Development · Pfizer
$875 per 30-minute call
Outlicensing questions point to Marion Fitzpatrick, Senior Director, Portfolio Leader Outlicensing, Business Development at Pfizer since 2010, who initiates and leads the teams preparing due diligence data rooms for outlicensing deals and, once a deal closes, leads the tech transfers in line with the legal agreement. Marion was Director (2003-2010) and Associate Director (2001-2003) at Pfizer and a CRA at Wellcome Trust (1991-1993).
Is this you? Claim your profile and get paid for calls.
Michael Flakus
LinkedInExperience: Senior Director, Worldwide Business Development · Pfizer
$943 per 30-minute call
Both the scientific and the deal-side view of how Pfizer business development has worked over many years come with Michael Flakus, a Scientist at Pfizer from 1995 to 2000 who holds Senior Director, Worldwide Business Development (since 2018) and Director, Worldwide Business Development (since 2000) there, the senior role sitting at director level in General Management.
Is this you? Claim your profile and get paid for calls.
Sumant Sherma
LinkedInExperience: Senior Director of Business Development · Pfizer
$875 per 30-minute call
From London, Sumant Sherma has been Senior Director of Business Development at Pfizer since 2013, with global responsibility for revenue goals, drafting term sheets and license agreements, financial modeling and pursuing M&A opportunities. Before Pfizer, Sumant was BD Manager at GSK (2010-2013), and suits questions on how a term sheet with Pfizer gets drafted and valued.
Is this you? Claim your profile and get paid for calls.
Susan Dunne
LinkedInExperience: Senior Director, Worldwide Business Development · Pfizer
$943 per 30-minute call
Post-close integration questions fit Susan Dunne most clearly, as Senior Director, Worldwide Business Development at Pfizer (since 2019), leading and overseeing enterprise-wide setup, planning and execution of multi-billion-dollar deal integrations. Susan was Director, International Treasury (2014-2019) and Global Financial Solutions Lead (2008-2014) at Pfizer and took a Divisional Strategy Lead, Pfizer Global Supply (Secondment) role in 2024.
Is this you? Claim your profile and get paid for calls.
Zeena Advani
LinkedInExperience: Director (Vaccines & Internal Medicine), Corporate Development · Pfizer
$673 per 30-minute call
Public and private acquisitions and asset divestitures are among the transactions Zeena Advani identifies, structures and negotiates as Director (Vaccines & Internal Medicine), Corporate Development at Pfizer since 2022. Zeena was Senior Manager (2020-2022) and Manager (2018-2020), Corporate Development at Pfizer, Senior Associate, Business Development at Prelude Fertility (2018) and a Private Equity Associate at Apax (2016-2018).
Is this you? Claim your profile and get paid for calls.
Choose the right perspective
A biotech with an oncology asset should start with Hilde Stubdal on search and evaluation, then Anne-Marie Mueller or Kelly Callahan in R&D business development. Outlicensing goes to Marion Fitzpatrick, post-close integration to Susan Dunne, acquisitions and divestitures in vaccines and internal medicine to Zeena Advani, and term sheets, license agreements and co-development deals to Sumant Sherma or Leslie Coney.
Questions to take into the conversation
- 01What does Pfizer's oncology search and evaluation team need to see in a data package before a first meeting turns into diligence?
- 02When Pfizer outlicenses an asset, how is the data room prepared and how is tech transfer handled after signing?
- 03How does Pfizer plan the integration of a multi-billion-dollar acquisition, and who owns it after close?
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot; roles marked former had ended by then. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.